Checkpoint Therapeutics initiated with a Buy at D. Boral Capital

D. Boral Capital initiated coverage of Checkpoint Therapeutics (CKPT) with a Buy rating and $9 price target The company’s lead drug, Unloxcty, was approved in December and is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1, preventing immune evasion by tumors band is engineered with a functional Fc region that retains antibody-dependent cellular cytotoxicity, the analyst tells investors in a research note. The firm says this can enhance immune-mediated killing of cancer cells, which positions the drug to compete in the now competitive immune-oncology marketplace.